Summary: In a four-arm trial in type 2 diabetic patients having laparoscopic colorectal surgery, only the low maintenance dose of dexmedetomidine gave better perioperative glucose regulation, while higher maintenance doses raised glucose, showing the effect is dose-dependent.
PICO Summary
| Element | Detail |
|---|---|
| Population | 80 patients with type 2 diabetes undergoing laparoscopic colorectal cancer radical resection; double-blind RCT, China. |
| Intervention | Dexmedetomidine, loading 1 µg/kg, then maintenance 0.25 (D1), 0.5 (D2), or 0.75 µg/kg/h (D3). |
| Comparison | Control group without dexmedetomidine. |
| Outcome | Glucose rose non-significantly over time in controls. The low-dose D1 maintained glucose without significant hyperglycaemia, while D2 and D3 showed significant rises and were significantly higher than control at mid-surgery time points. The authors conclude a loading dose of 1 µg/kg with maintenance 0.25 µg/kg/h gives better glucose regulation without increasing hyperglycaemia, adverse effects, or extubation time. |
Dexmedetomidine and perioperative glucose in T2DM
RCT · type 2 diabetes · colorectal surgery
Only the low maintenance dose (0.25 ug/kg/h) kept perioperative glucose steady without exceeding control; higher doses raised glucose above control mid-surgery. The effect is dose-dependent.
Expert Commentary
This is a useful dose-ranging trial whose headline must not be flattened into dexmedetomidine simply helps glucose, because the real lesson is that dose decides direction. At a low maintenance rate the drug was associated with steadier perioperative glucose, plausibly by blunting the sympathetic surgical stress response, but at the two higher maintenance rates glucose actually rose and exceeded control at mid-operative time points. That biphasic, dose-dependent pattern is the clinically important message and the reason a one-line summary would mislead. I would treat the favourable low-dose finding as encouraging rather than definitive given the small sample of eighty split across four arms and a single procedure type, which limits both power and generalisability, and the surrogate nature of intraoperative glucose readings rather than patient outcomes. Can I use this with my patients? Tentatively and at the right dose. For a diabetic patient where dexmedetomidine is already being considered for its anaesthetic and sympatholytic properties, this supports favouring a lower maintenance infusion for glycaemic steadiness, while being clear that higher infusion rates may worsen glucose and that larger trials across procedure types are needed before firm recommendations.
References
Dai W, Zhou J, Qu L, He K. Effect of dexmedetomidine on perioperative blood glucose regulation in type 2 diabetic patients undergoing laparoscopic colorectal cancer radical resection: a randomised double-blinded controlled trial. Trials. 2025;26(1):362. doi:10.1186/s13063-025-09094-0